Log In / Register
FDA approval of SBECD-enabled Brexanolone
27 March, 2019
Sage Therapeutics, a biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved ZULRESSO
(brexanolone) injection for the treatment of postpartum depression (PPD).
Captisol is used for improving solubility, stability and bioavailability of the drug.
Read more on Cyclodexrin News blog
BACK TO NEWS